Compound Panax Notoginseng Granule

PreclinicalSmall molecule

GGuangdong Provincial Hospital of Traditional Chinese Medicine

Compound Panax Notoginseng Granule is one of 4 small molecule programs targeting Gut Microbiota. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gut MicrobiotaUnknown status

Gut MicrobiotaPreclinical

Unknown status

Competition

Competitive Landscape

5 competitors in Gut Microbiota

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Phase 3

3 2

MS-20

MMicrobio Co Ltd

Preclinical

1 3

Compound Panax Notoginseng Granule

GGuangdong Provincial Hospital of Traditional Chinese Medicine

Preclinical

1 4

Application of SHB001

UUniversity of Zurich

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gut Microbiota1 trial

Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide

Unknown status·GGuangdong Provincial Hospital of Traditional Chinese Medicine·N/A·NCT03186625·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Compound Panax Notoginseng Granule. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Compound Panax Notoginseng Granule compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Compound Panax Notoginseng Granule. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Provincial Hospital of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGuangdong Provincial Hospital of Traditional Chinese Medicine

Compound Panax Notoginseng Granule

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gut Microbiota1 trial

References

Drug Info

Quick Facts

Related News